NO20100333L - Behandling av nevrotiske forstyrrelser - Google Patents

Behandling av nevrotiske forstyrrelser

Info

Publication number
NO20100333L
NO20100333L NO20100333A NO20100333A NO20100333L NO 20100333 L NO20100333 L NO 20100333L NO 20100333 A NO20100333 A NO 20100333A NO 20100333 A NO20100333 A NO 20100333A NO 20100333 L NO20100333 L NO 20100333L
Authority
NO
Norway
Prior art keywords
treatment
disorder
disorders
neurotic disorders
neurotic
Prior art date
Application number
NO20100333A
Other languages
English (en)
Inventor
Connie Sanchez
Sandra Hogg
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8099796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20100333(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO20100333L publication Critical patent/NO20100333L/no
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

Anvendelse av escitalopram (S-(+)-enantiomer av citalopram) eller et farmasøytisk akseptabelt salt derav for fremstillingen av et medikament nyttig i behandlingen av nevrotiske forstyrrelser tilveiebringes. Inklusive angsttilstander,spesielt en generell angstforstyrrelse og sosial angstforstyrrelse, posttraumatisk stressforstyrrelse, obsessiv-kompulsiv forstyrrelse og panikkanfall.
NO20100333A 1999-07-08 2010-03-10 Behandling av nevrotiske forstyrrelser NO20100333L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199900991 1999-07-08
PCT/DK2000/000377 WO2001003694A1 (en) 1999-07-08 2000-07-07 Treatment of neurotic disorders

Publications (1)

Publication Number Publication Date
NO20100333L true NO20100333L (no) 2002-01-07

Family

ID=8099796

Family Applications (4)

Application Number Title Priority Date Filing Date
NO20020062A NO329021B1 (no) 1999-07-08 2002-01-07 Anvendelse av escitalopram for behandling av generell angstforstyrrelse
NO20100333A NO20100333L (no) 1999-07-08 2010-03-10 Behandling av nevrotiske forstyrrelser
NO20100334A NO20100334L (no) 1999-07-08 2010-03-10 Behandling av nevrotiske forstyrrelser
NO20100335A NO20100335L (no) 1999-07-08 2010-03-10 Behandling av nevrotiske forstyrrelser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20020062A NO329021B1 (no) 1999-07-08 2002-01-07 Anvendelse av escitalopram for behandling av generell angstforstyrrelse

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20100334A NO20100334L (no) 1999-07-08 2010-03-10 Behandling av nevrotiske forstyrrelser
NO20100335A NO20100335L (no) 1999-07-08 2010-03-10 Behandling av nevrotiske forstyrrelser

Country Status (38)

Country Link
US (6) US7271194B2 (no)
EP (4) EP1200081B1 (no)
JP (1) JP4773011B2 (no)
KR (1) KR100604176B1 (no)
CN (1) CN1198610C (no)
AR (1) AR021155A1 (no)
AT (1) ATE339955T1 (no)
AU (6) AU782514B2 (no)
BG (4) BG110468A (no)
BR (1) BR0011578A (no)
CA (4) CA2687392A1 (no)
CL (3) CL2008003938A1 (no)
CO (1) CO5190674A1 (no)
CY (1) CY1105806T1 (no)
CZ (1) CZ200270A3 (no)
DE (1) DE60030861T2 (no)
DK (1) DK1200081T3 (no)
EA (1) EA006555B1 (no)
ES (1) ES2272298T3 (no)
HK (1) HK1048069B (no)
HR (1) HRP20010820A2 (no)
HU (1) HUP0201791A3 (no)
IL (5) IL146131A0 (no)
IS (1) IS6137A (no)
ME (2) MEP2508A (no)
MX (1) MXPA01011626A (no)
MY (1) MY143278A (no)
NO (4) NO329021B1 (no)
PL (1) PL352030A1 (no)
PT (1) PT1200081E (no)
SI (1) SI1200081T1 (no)
SK (1) SK82002A3 (no)
TR (4) TR200200014T2 (no)
TW (1) TWI232101B (no)
UA (1) UA77645C2 (no)
WO (1) WO2001003694A1 (no)
YU (1) YU78701A (no)
ZA (1) ZA200108856B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
SK2022003A3 (en) * 2000-07-21 2003-06-03 Lundbeck & Co As H Novel compounds and their use as glycine transport inhibitors
MEP5908A (xx) * 2001-05-01 2010-02-10 Lundbeck & Co As H Upotreba enantiomerno čistog escitaloprama
RS8304A (en) 2001-07-31 2006-12-15 H.Lundbeck A/S. Crystalline composition containing escitalopram
WO2004004721A1 (en) * 2002-07-08 2004-01-15 University Of Florida Use of ssri inhibitors to prevent or ameliorate trauma-related psychological disorders
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
AU2003287919B2 (en) * 2002-12-23 2009-11-12 H. Lundbeck A/S Escitalopram hydrobromide and a method for the preparation thereof
TR200504022T1 (tr) * 2003-03-24 2006-08-21 Hetero Drugs Limited (S)-sitalopram oksalatın yeni sıvı kristal formları.
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
EP1708790B1 (en) * 2003-12-02 2010-04-21 PharmaNeuroBoost N.V. Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2007053796A2 (en) 2005-10-14 2007-05-10 Forest Laboratories, Inc. Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143703A (no) 1965-03-18
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4439545A (en) 1981-11-19 1984-03-27 Societe D "Expansion Scientifique "Expansia" Acrylic copolymers of N-acryloylpolymethyleneimines or N-acryloyldialkylamides, N,N'-acryloyldiaminoalcanes and N-acryloylaminoacids (or esters) their preparation and use as cation exchangers
GB8419963D0 (en) 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
DK213290D0 (da) * 1990-09-06 1990-09-06 Lundbeck & Co As H Treatment of cerebrovascular disorders
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
US5708035A (en) 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
WO1992018005A1 (en) 1991-04-16 1992-10-29 National Institutes Of Health Method of treating trichotillomania and onychophagia
ES2197144T3 (es) 1991-11-15 2004-01-01 Sepracor Inc. Uso del isomero s(+) puro de fluoxetina para la preparacion de un medicamento contra la migraña.
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
AU4918796A (en) * 1995-02-10 1996-08-27 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) 1995-04-27 1995-04-27 Astra Ab A new combination
ATE192042T1 (de) 1995-08-16 2000-05-15 Lilly Co Eli Potenzierung von serotonin-wirkstoffresponz
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5912256A (en) * 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703375D0 (sv) 1997-09-18 1997-09-18 Astra Ab A new combination
SE9703379D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
WO1998019512A2 (en) * 1997-11-11 1998-05-14 H. Lundbeck A/S Method for the preparation of citalopram
PT957099E (pt) * 1998-04-15 2003-02-28 Pfizer Prod Inc Carboxamidas heterociclicas
EP1100501A4 (en) * 1998-06-30 2002-12-04 Lilly Co Eli PYRROLIDINE AND PYRROLIDINE DERIVATIVES INFLUENTING THE SYSTEMS ASSOCIATED WITH SEROTONIN
CA2336962A1 (en) 1998-07-13 2000-01-20 Alan Mueller Methods and compounds for treating depression and other disorders
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
EP1096927A4 (en) 1998-07-16 2002-09-04 Massachusetts Inst Technology STRESS TREATMENT COMPOSITION
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
SE9803157D0 (sv) 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803158D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
IL142346A0 (en) * 1998-10-20 2002-03-10 Lundbeck & Co As H Method for the preparation of citalopram
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
TR200102957T2 (tr) * 1999-04-14 2004-12-21 H. Lundbeck A/S Sitalopram hazırlanması için metod.
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
WO2001080845A2 (en) 2000-04-24 2001-11-01 Aryx Therapeutics (2-aminoethyl) oxime derivatives for the treatment of depression
JP2002361405A (ja) * 2000-09-25 2002-12-18 Showa Denko Kk 熱交換器の製造方法
MEP5908A (xx) * 2001-05-01 2010-02-10 Lundbeck & Co As H Upotreba enantiomerno čistog escitaloprama

Also Published As

Publication number Publication date
CL2008003939A1 (es) 2009-06-05
EA200200137A1 (ru) 2002-06-27
NO329021B1 (no) 2010-07-26
TR200402275T2 (tr) 2005-03-21
AU2005202684B2 (en) 2009-01-15
US20050101665A1 (en) 2005-05-12
DE60030861T2 (de) 2007-05-03
KR100604176B1 (ko) 2006-07-25
CL2008003938A1 (es) 2009-05-22
NO20100334L (no) 2002-01-07
CA2687396A1 (en) 2001-01-18
SK82002A3 (en) 2002-07-02
TR200402277T2 (tr) 2005-01-24
CA2687394A1 (en) 2001-01-18
BG106279A (bg) 2002-08-30
JP4773011B2 (ja) 2011-09-14
AU2005202686A1 (en) 2005-07-14
CY1105806T1 (el) 2011-02-02
AU2005202684A1 (en) 2005-07-14
EP1440691A2 (en) 2004-07-28
TR200402276T2 (tr) 2005-01-24
AU782514B2 (en) 2005-08-04
NO20020062L (no) 2002-01-07
SI1200081T1 (sl) 2007-02-28
CN1198610C (zh) 2005-04-27
AU2005202685A1 (en) 2005-07-14
ZA200108856B (en) 2002-12-24
NO20100335L (no) 2002-01-07
US7271194B2 (en) 2007-09-18
JP2003504332A (ja) 2003-02-04
US7265151B2 (en) 2007-09-04
KR20020015346A (ko) 2002-02-27
EP1440689A2 (en) 2004-07-28
HK1048069A1 (en) 2003-03-21
PL352030A1 (en) 2003-07-28
YU78701A (sh) 2004-03-12
DK1200081T3 (da) 2006-12-27
MEP2508A (xx) 2010-02-10
AU5806100A (en) 2001-01-30
DE60030861D1 (de) 2006-11-02
UA77645C2 (en) 2007-01-15
CA2373757A1 (en) 2001-01-18
IL146131A0 (en) 2002-07-25
HRP20010820A2 (en) 2003-08-31
WO2001003694A1 (en) 2001-01-18
CO5190674A1 (es) 2002-08-29
EP1200081B1 (en) 2006-09-20
IL146131A (en) 2007-02-11
AU2005202686B2 (en) 2009-01-15
BG110468A (en) 2010-01-29
IL170194A (en) 2010-05-31
AU2005202685B2 (en) 2009-01-15
US20040029956A1 (en) 2004-02-12
MY143278A (en) 2011-04-15
TR200200014T2 (tr) 2002-05-21
CZ200270A3 (cs) 2002-04-17
EA006555B1 (ru) 2006-02-24
US6960613B2 (en) 2005-11-01
HK1048069B (zh) 2005-12-16
AU2008264188A1 (en) 2009-05-07
EP1440690A2 (en) 2004-07-28
US20040029958A1 (en) 2004-02-12
ES2272298T3 (es) 2007-05-01
US20070276035A1 (en) 2007-11-29
HUP0201791A2 (en) 2002-10-28
EP1200081A1 (en) 2002-05-02
TWI232101B (en) 2005-05-11
IS6137A (is) 2001-10-30
BR0011578A (pt) 2002-03-26
CN1360501A (zh) 2002-07-24
AR021155A1 (es) 2002-06-12
CA2373757C (en) 2010-01-05
EP1440691A3 (en) 2004-08-25
BG110466A (en) 2010-01-29
CL2008003941A1 (es) 2009-05-22
US20040029957A1 (en) 2004-02-12
EP1440690A3 (en) 2004-08-18
ATE339955T1 (de) 2006-10-15
MXPA01011626A (es) 2002-06-04
ME00032B (me) 2010-02-10
NO20020062D0 (no) 2002-01-07
BG110467A (en) 2010-01-29
AU2008264182A1 (en) 2009-01-29
IL170193A (en) 2010-04-29
CA2687392A1 (en) 2001-01-18
PT1200081E (pt) 2007-01-31
IL170192A (en) 2010-04-29
US20020086899A1 (en) 2002-07-04
HUP0201791A3 (en) 2005-02-28
EP1440689A3 (en) 2004-08-25

Similar Documents

Publication Publication Date Title
NO20100333L (no) Behandling av nevrotiske forstyrrelser
DK0705099T3 (da) Anvendelse af modafinil til behandling af søvnapnø og åndedrætslidelser af central oprindelse
BR0209580A (pt) Derivados de ciclohexan-1, 4 diamina substituìdos
ATE470446T1 (de) Neues verfahren und zusammensetzungen zur örtlichen behandlung von meniere-krankheit, tinnitus und/oder hörverlust
DE69034149D1 (de) Verwendung von Sertralin zur Behandlung von posttraumatischen Stresserkrankungen
ATE334670T1 (de) Verwendung von mek-inhibitoren zur herstellung eines arzneimittels gegen negativstrang-rna-viren infektionen
NO20035116D0 (no) 4-(fenylpiperidin-4-yliden-metyl)-benzamidderivater og deres anvendelse forbehandling av smerte, angst eller gastrointestinale forstyrrelser
HUP0200152A2 (hu) KQT1 csatornák gátlóinak alkalmazása parazita férgek és ektoparaziták által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
BR0213856A (pt) Fatores ativadores de plasminogênio não-neurotóxicos para o tratamento do ataque de apoplexia
NO20015228L (no) Anvendelse av saredutant og de farmasöytisk aksepterbare salter derav for fremstilling av medikamenter anvendt for åbehandle eller forebygge sinnslidelser, tilpasningslidelser ellerblandede angst-depresjonslidelser
ITMI922263A1 (it) Ammine eterocicliche utili nella terapia dell'asma e dell'infiammazione delle vie aeree
NO20035115D0 (no) 4-(fenylpiperidin-4-yliden-metyl)-benzamidderivater og deres anvendelse forbehandling av smerte, angst eller gastrointestinale forstyrrelser
HUP0401934A2 (hu) Enantiomerekben dúsított demetil- és didemetil- citalopram metabolitok alkalmazása depresszió és más központi idegrendszeri rendellenességek esetében
DK0869807T3 (da) Anvendelse af et medikament og brug af en stofblanding til fremstilling af et medikament
ATE334989T1 (de) Antidepressive azaheterocyclylmethyl-derivate von 2,3-dihydro-1,4-dioxino 2,3-föchinoxalin
NO20035117D0 (no) 4-(fenylpiperidin-4-yliden-metyl)-benzamidderivater og deres anvendelse forbehandling av smerte, angst eller gastrointestinale forstyrrelser
EA200001162A1 (ru) Новые лекарственные комбинации ингибиторов повторного поглощения норадреналина (иппна), предпочтительно ребоксетина и пиндолола
ATE336987T1 (de) Gelzubereitung enthaltend einen gelösten oder suspendierten wirkstoff,insbesondere zur anwendung auf einer schleimhaut und herstellungsverfahren
DE50105253D1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
DE60024408D1 (de) Verwendung von trizyklischen antidepressiva zur behandlung von kopfschmerzen
DE50012667D1 (de) Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von ischämischen zuständen
EA200501282A1 (ru) Применение эсциталопрама для лечения расстройства, связанного с посттравматическим стрессом
DE60305018D1 (de) Citalopram zur behandlung von bluthochdruck
GB0102647D0 (en) Cosmetic skin care preparation
EA200501281A1 (ru) Применение эсциталопрама для лечения расстройства, связанного с социальной тревогой

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application